We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Medical Mktg | LSE:MMG | London | Ordinary Share | GB0004150685 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.75 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number : 0221H
Medical Marketing Int'l Group PLC
30 October 2008
Investment in Genvax Limited
Thursday 30 October 2008 - Medical Marketing International Group plc ("MMI" or the "Company") (AIM:MMG), the life sciences company
focused on the development of drugs for cancer, today announces that it has agreed a further investment of up to £427,500 in its subsidiary,
Genvax Limited, by subscribing for up to 2,850 shares at £150 per share.
The investment, which is staged and is conditional on certain commercial milestones being achieved, follows the announcement on 31 July
2008 that the Company had raised gross proceeds of £0.95 million to fund the development programmes of its cancer vaccine and ruthenium
chemotherapy technologies. Once fully subscribed, MMI's stake in Genvax will increase from 58% to 66%. The first £67,500 of the investment
will be made in 2008.
Commenting on the investment, Mark Burton, Chief Technical Officer, said "We have previously reported that we have a clear strategy to
develop a broadly-based oncology company and this investment will enable Genvax to develop its DNA vaccine technology towards
proof-of-principle prior to onward out-licensing to pharmaceutical partners."
Enquiries:
Medical Marketing International Group plc
Phil Cartmell, Non-executive Chairman Tel: +44 (0) 1223 477 677
Mark Burton, Chief Technical Officer
Rob Sprawson, Chief Financial Officer
FinnCap
Sam Smith/Charlie Cunningham Tel: +44 (0)20 7600 1658
Financial Dynamics
David Yates/Emma Thompson Tel: +44 (0)20 7831 3113
About MMI
Medical Marketing International Group plc ("MMI") is a life sciences company that identifies, acquires and develops world-class
compounds and technologies for the treatment of cancer. The Company manages the preclinical and early clinical development of drug
candidates before pursuing licensing partners to manage late-stage development. Please visit www.mmigroup.co.uk for further information.
Notwithstanding the inclusion on this release by MMI of a website address and/or another electronic address, MMI does not accept any
notices or any other documents or communication via its website or other electronic address. All such notices, documents or communication
shall be in hard copy format only. Accordingly the provisions of section 333 Companies Act 2006 allowing persons to communicate with MMI
electronically shall not apply to MMI.
About Genvax
Genvax Limited has an exclusive world-wide licence from Cancer Research Technology to intellectual property for DNA vaccines that was
developed at the University of Southampton.
-ends-
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCWUGPGUUPRUBU
1 Year Medical Mktg Chart |
1 Month Medical Mktg Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
